- Home
- BTTC vs CNSP Comparison
BTTC vs CNSP Comparison
Compare BTTC & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTTC | CNSP |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 8.5M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BTTC | CNSP |
|---|---|---|
| Price | $0.41 | $5.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 659.5K | 6.3K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $1.90 |
| 52 Week High | $11.22 | $10.59 |
Technical Indicators
Market Signals| Indicator | BTTC | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 21.60 | 56.62 |
| Support Level | N/A | $4.63 |
| Resistance Level | $0.85 | $6.19 |
| Average True Range (ATR) | 0.06 | 0.39 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.68 | 76.91 |
Price Performance
Historical ComparisonAbout BTTC Black Titan Corporation Ordinary Shares
Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.